Vaxil Bio Ltd.
Loading stock data...
Stock Performance
Price History
-
Drag to select time range
-
Market Data
Market Cap
383,541
P/E Ratio
-
52-Week High
-
52-Week Low
-
Avg Volume
-
Beta
-
Forward P/E
-
Dividend Yield
-
EV/Revenue
-
Price/Book
-
Business Overview
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. The company is headquartered in Toronto, Canada.
Healthcare
Biotechnology
TSXV
Key Financial Metrics
-
Revenue
-178,000
Net Income
C$-0.05
EPS (Diluted)
-240,000
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-
Net Profit Margin
-
EBITDA
-196,000
Returns & Efficiency
Return on Assets (ROA)
-24.3%
Return on Equity (ROE)
-24.9%
Dividend Yield
-
Payout Ratio
-
Financial Health
Total Assets
733,000
Total Debt
-
Debt to Equity
-
Current Ratio
43.12
Company Info
| Industry | Biotechnology |
| HQ | Toronto, Canada |
| Fiscal Year End | 1735603200 |
| Currency | CAD |
Peers
Bausch + Lomb Corporation
BLCO.TO
7.9B
P/E: --
Bausch Health Companies Inc.
BHC.TO
2.5B
P/E: 12.0
Extendicare Inc.
EXE.TO
2.5B
P/E: 23.7
Sienna Senior Living Inc.
SIA.TO
2.2B
P/E: 53.2
Cronos Group Inc.
CRON.TO
1.4B
P/E: 24.1
Tilray Brands, Inc.
TLRY.TO
1.2B
P/E: --
WELL Health Technologies Corp.
WELL.TO
1.1B
P/E: --
Knight Therapeutics Inc.
GUD.TO
631.8M
P/E: --
Insider Activity
Sentiment
Bullish
Shares Bought
2,632,107
Shares Sold
0
Total Transactions
5
SEDAR+ Filings
View All Filings8
Annual Reports
27
Quarterly Reports
35
MD&A
40
News Releases
1
Material Changes
12
Governance
72
Certifications
46
Other
●
2018-02-26
Interactive Charts
Company Profile
General Information
| Company Name | Vaxil Bio Ltd. |
| Ticker | VXL.V |
| Exchange | TSXV |
| Sector | Healthcare |
| Industry | Biotechnology |
| Headquarters | Toronto, Canada |
| Fiscal Year End | 1735603200 |
| Currency | CAD |
Financial Summary
| Market Cap | 383,541 |
| Revenue | N/A |
| Net Income | -178,000 |
| P/E Ratio | N/A |
| EPS (Diluted) | C$-0.05 |
| Net Margin | N/A |
| ROE | -24.9% |
| Dividend Yield | N/A |
Business Description
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. The company is headquartered in Toronto, Canada.